BREAST CANCER

The ELEVATE trial found combining elacestrant with everolimus or ribociclib is safe and effective for ER+/HER2- metastatic breast cancer.

Vepdegestrant shows significant progression-free survival benefits over fulvestrant in advanced breast cancer, highlighting its potential as a targeted treatment option.

Massimo Cristofanilli, MD, discusses the role of cell-free DNA in breast cancer.

A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing promising trial results.

Ipatasertib combined with fulvestrant significantly extends progression-free survival in ER-positive, HER2-negative metastatic breast cancer patients post-CDK4/6 therapy.

Higher pretreatment HER2 amplicon mRNA and HER2 protein levels predicted improved time to next treatment with T-DXd in metastatic breast cancer. Conversely, higher TOPO1 protein correlated with worse outcomes.

Ribociclib combined with aromatase inhibitors shows significant survival benefits for early-stage hormone receptor-positive breast cancer, enhancing treatment outcomes across patient demographics.

EMBER-3 trial results show imlunestrant, alone or with abemaciclib, improves patient-reported outcomes for ER+/HER2- advanced breast cancer after endocrine therapy.

The NeoSTAR trial showed neoadjuvant sacituzumab govitecan and pembrolizumab achieved a 32% pCR rate in early-stage TNBC, with promising efficacy and a tolerable safety profile.

Camizestrant plus CDK4/6 inhibition improved progression-free survival when given to patients with ESR1-mutant ER+/HER2– breast cancer in the SERENA-6 trial.

Erin Cobain, MD, discusses findings from a study exploring the differences in diagnosis and treatment of high-risk breast cancer in Black and White patients.

Sara M. Tolaney, MD, MPH, shares new data from the ASCENT-04 trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer.

Vepdegestrant significantly improved progression-free survival vs fulvestrant in pretreated ESR1-mutant, ER-positiver, HER2-negative advanced breast cancer.

Sacituzumab govitecan & pembrolizumab significantly improved PFS in PD-L1+ advanced TNBC vs. chemo/pembrolizumab in the ASCENT-04 study.

Sara M. Tolaney, MD, MPH, highlights a transformative year for breast cancer research at this year’s ASCO Annual Meeting.

In ASCENT-03, sacituzumab govitecan significantly extended progression-free survival in metastatic triple-negative breast cancer not eligible for PD-(L)1 inhibitors.

INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant advanced breast cancer.

During a Community Case Forum event, Antoinette R. Tan, MD, MHS, discussed the DESTINY-Breast04 and DESTINY-Breast06 trials in HER2-low and -ultralow breast cancer.

Samuraciclib improved progression-free survival in HR+ advanced breast cancer patients without TP53 mutations or liver metastases.

Findings from the TROPION-Lung04 study were presented at the ESMO Targeted Anticancer Therapies Congress 2025 in March.

Adding pertuzumab to standard of care improved survival by 17% in patients with early-stage HER2-positive breast cancer.

During a live event, Gregory Vidal, MD, PhD, discussed the adjuvant trials of abemaciclib and ribociclib and how their different dosing approaches and safety profiles can affect their usage in breast cancer.

T-DXd monotherapy and T-DXd plus pertuzumab continue to show robust efficacy in HER2-positive metastatic breast cancer.

During a live event, Megan Kruse, MD, discussed sacituzumab govitecan's benefit, dosing, toxicity, and an ongoing earlier-line trial in metastatic breast cancer.

A phase 1b/2 trial in triple-negative breast cancer will assess LP-184 alone and with a PARP inhibitor in advanced cases.